Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

Completed

Brief Summary: RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.

PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.

Detailed Description: OBJECTIVES:

* To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.

Recruitment & Eligibility

Inclusion Criteria

Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

o Newly diagnosed disease
Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center
Fertile patients must use effective contraception
Able to lie flat for 90 minutes
Able to fulfill the requirements of the study

Exclusion Criteria

Not pregnant or nursing
No pacemaker
No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)
No metallic foreign body not approved for MRI
No known hypersensitivity to gadolinium contrast or other required drugs in the study
No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study
No prior chemotherapy
No prior radiotherapy to mantle or mediastinum

Arm && Interventions

Group	Intervention	Description
Observational	contrast-enhanced magnetic resonance imaging	Only had observational arm

Primary Outcome Measures

Name	Time	Method
Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy	cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.	A reduction of 10% in left ventricular ejection fraction (LVEF) between the two cMRI studies was considered a subclinical functional event. New or progressive myocardial delayed enhancement within ≥1 segment was deemed as a subclinical structural event. Global left ventricle (LV) radial, circumferential, and longitudinal strain data for each patient were compared between cMRI-1 and cMRI-2. The study had a fixed endpoint (3 months post-treatment)

Secondary Outcome Measures